Mutant isocitrate dehydrogenase driven metabolic reprogramming results in therapeutic vulnerability to lactate dehydrogenase inhibition

doi:10.1158/1538-7445.AM2020-3737

	Mutant isocitrate dehydrogenase driven metabolic reprogramming results in therapeutic vulnerability to lactate dehydrogenase inhibition
	Bi, Aiwei 1; Xu, Jun 1; Jin, Nan 1; Lan, Xiaojing 1; Tang, Shuai 1; Shou, Matthew 3; Liu, Jia 1; Ding, Jian 1; Geng, Meiyu 1; Lin, Shuhai 2
刊名	CANCER RESEARCH
	2020-08-01
卷号	80 期号:16 页码:2
ISSN号	0008-5472
DOI	10.1158/1538-7445.AM2020-3737
WOS研究方向	Oncology
语种	英语
出版者	AMER ASSOC CANCER RESEARCH
WOS记录号	WOS:000590059305309
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/295709]
专题	中国科学院上海药物研究所
作者单位	1.Shanghai Inst Mat Med, Shanghai, Peoples R China 2.Xiamen Univ, Xiamen, Peoples R China 3.Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA
推荐引用方式 GB/T 7714	Bi, Aiwei,Xu, Jun,Jin, Nan,et al. Mutant isocitrate dehydrogenase driven metabolic reprogramming results in therapeutic vulnerability to lactate dehydrogenase inhibition[J]. CANCER RESEARCH,2020,80(16):2.
APA	Bi, Aiwei.,Xu, Jun.,Jin, Nan.,Lan, Xiaojing.,Tang, Shuai.,...&Huang, Min.(2020).Mutant isocitrate dehydrogenase driven metabolic reprogramming results in therapeutic vulnerability to lactate dehydrogenase inhibition.CANCER RESEARCH,80(16),2.
MLA	Bi, Aiwei,et al."Mutant isocitrate dehydrogenase driven metabolic reprogramming results in therapeutic vulnerability to lactate dehydrogenase inhibition".CANCER RESEARCH 80.16(2020):2.